Overview Effect of MD1003 in Amyotrophic Lateral Sclerosis Status: Completed Trial end date: 2017-12-01 Target enrollment: Participant gender: Summary This is a 6-month double blind randomized 2:1 placebo-controlled study with two arms (placebo, biotin 300 mg/day). The study will be followed by a 6-month extension phase during which all patients will receive biotin 300 mg/day. Phase: Phase 2 Details Lead Sponsor: MedDay Pharmaceuticals SATreatments: BiotinCarboxymethylcellulose Sodium